Dr. Reddy’s Laboratories (DRREDDY) Q2 20/21 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 20/21 earnings summary
23 Oct, 2026Executive summary
Highest-ever quarterly sales of Rs. 4,897 cr, with healthy EBITDA margins; reported sales grew 2% YoY and 11% QoQ.
Excluding Rs. 723 cr of proprietary-products out-licensing income in Q2 FY20, sales growth was 20% YoY.
Financial highlights
EBITDA was Rs. 1,267 cr, down 12% YoY and up 9% QoQ; PBT was Rs. 862 cr, up 12% YoY and down 2% QoQ.
PAT was Rs. 762 cr, down 30% YoY and up 32% QoQ.
Outlook and guidance
Priorities include uninterrupted operations during COVID-19, COVID-19 treatment development and launches, market-leading growth, a stronger product pipeline, productivity, innovation, digitalization and strategic execution.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Dr. Reddy’s Laboratories
- Record FY21 revenue and EBITDA; Sputnik V launch broadened the Covid portfolio.DRREDDY
Q4 20/21 - Record FY23 sales and EBITDA, backed by launches, pipeline progress and strong cash generation.DRREDDYQ4 22/23
- Revenue rose 29% as launches and market gains fueled record Q1 FY24 profitability.DRREDDYQ1 23/24
- FY23 growth and cash generation support a 1.5bn-patient, innovation-led expansion.DRREDDYInvestor presentation
- Record Q2 sales and broad-based growth, backed by launches and robust profitability.DRREDDYQ2 23/24
- Record FY24 revenues and profits, with Q4 growth led by US volumes and launches.DRREDDYQ4 23/24
- Revenue rose 7% as launches and market-share gains supported Q3FY24 growth.DRREDDYQ3 23/24
- Underlying growth and a 20.6% EBITDA margin amid lenalidomide and semaglutide headwinds.DRREDDYQ2 26/27
- Record ₹7,673 Cr revenue, 28.2% EBITDA margin, and major strategic deals in Q1FY25.DRREDDYQ1 24/25